Table 1.
Overview of retrospective analyses of active surveillance trials’ eligibility criteria in relation to upstage rates to invasive cancer in the surgical resection specimen, after an initial diagnosis of pure DCIS at the biopsy level
| Ref. | Year of publication | Active surveillance eligibility criteria | Number of samples according to eligibility criteria n | Total upstage rate to invasive cancer n (%) | Upstage rate to invasive cancer according to nuclear grade n (%) |
|---|---|---|---|---|---|
| 51 | 2013 | LoRis | 31 | 0 (0) |
|
| 52 | 2016 | LoRis | 296 | 58 (20) |
|
| 53 | 2017 | LoRis | 74 | 5 (7) |
|
| LORD | 10 | 1 (10) |
|
||
| COMET | 81 | 5 (6) |
|
||
| 54 | 2018 | LoRis | 25 | 6 (24) | Not mentioned in this report |
| COMET | 23 | 5 (22) | Not mentioned in this report | ||
| 55 | 2017 | LoRis | 241 | 16 (7) | Not mentioned in this report |
Abbreviations: COMET, comparison of operative to monitoring and endocrine therapy trial; DCIS, ductal carcinoma in situ; LORD, low‐risk DCIS trial; LoRis, low‐risk DCIS trial; Ref, reference.